INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 25 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $2,287,000 | -3.8% | 3,300,000 | 0.0% | 0.02% | -5.3% |
| Q2 2020 | $2,377,000 | -17.1% | 3,300,000 | 0.0% | 0.02% | -26.9% |
| Q1 2020 | $2,868,000 | -34.6% | 3,300,000 | 0.0% | 0.03% | -7.1% |
| Q4 2019 | $4,382,000 | +46.4% | 3,300,000 | 0.0% | 0.03% | +40.0% |
| Q3 2019 | $2,994,000 | – | 3,300,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PenderFund Capital Management Ltd. | 9,295,000 | $12,549 | 3.76% |
| Context Capital Management, LLC | 23,076 | $22,612 | 1.81% |
| Weiss Asset Management LP | 16,160,000 | $15,847,974 | 0.94% |
| Anson Funds Management LP | 4,000,000 | $3,920,000 | 0.79% |
| SYQUANT CAPITAL SAS | 2,000,000 | $1,961 | 0.77% |
| DG Capital Management, LLC | 1,101,000 | $1,082,834 | 0.59% |
| Skaana Management L.P. | 2,000,000 | $1,957,600 | 0.48% |
| AQR Arbitrage LLC | 6,130,000 | $6,046,019 | 0.27% |
| OAKTREE CAPITAL MANAGEMENT LP | 7,295,000 | $7,195,058 | 0.10% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $220,658 | 0.04% |